ST Pharm Joins TIDES USA 2025, Ramping Up Efforts in North American RNA Therapeutics Market

ST Pharm Showcases RNA-Based Therapeutic Platform Technologies at TIDES USA 2025

ST Pharm (CEO Mooje Sung) announced on the 26th that it participated in TIDES USA 2025, held from May 19 to 22 (local time) in San Diego, to promote its technological capabilities in RNA-based therapeutics such as mRNA and oligonucleotides.

TIDES USA is the world’s largest and most prestigious international conference dedicated to oligonucleotide and peptide therapeutics. The event brings together global pharmaceutical companies and biotech firms to share the latest research, manufacturing technologies, and market trends.

At this year’s conference, ST Pharm introduced its technological strengths and competitive advantages across the entire RNA-based therapeutic platform business—including mRNA, oligonucleotides, small molecules, guide RNAs (gRNAs), and monomers—to representatives from multinational pharmaceutical and biotech companies.

The company held numerous business meetings aimed at strengthening co-development and CDMO (Contract Development and Manufacturing Organization) partnerships. These engagements also served as a springboard for expanding its presence in the U.S. market, leveraging its RNA-based CDMO capabilities.

During the event, Executive Vice President Seokwoo Choi, Head of the Business Division at ST Pharm, delivered a featured presentation titled “The Solution Provider for RNA-Based Therapeutics.” His talk highlighted global trends in the RNA therapeutics market and provided an overview of ST Pharm’s core technologies and its end-to-end CDMO value chain, drawing significant interest from attendees.

Additionally, ST Pharm presented three technical posters showcasing its advanced innovations:

Development of Alternative BCDP Reagents for the Synthesis of 5′-Terminal Phosphate Oligonucleotides: Application in the Synthesis of SmartCap®, a novel mRNA capping reagent designed to improve oligonucleotide production efficiency;
Single-Nucleotide Resolution of sgRNAs via MS-Compatible Ion-Pair Reversed-Phase (IPRP) LC, a new technology enabling high-precision analysis of sgRNAs, key components in gene editing tools;
Next Generation Oligo Manufacture: Enzyme Hybrid Technology, an advanced method combining enzymatic and chemical synthesis to produce next-generation oligonucleotides.

A company representative commented, “TIDES USA 2025 was a meaningful opportunity for us to reaffirm ST Pharm’s global competitiveness in the RNA-based therapeutics field. We will continue to drive technological innovation and expand our global footprint as a specialized CDMO, contributing to the growth of the RNA therapeutics industry.”